Plasma biomarkers of clinical response during chemotherapy plus combination antiretroviral therapy (cART) in HIV+ patients with advanced Kaposi sarcoma

Oncotarget

Volumn 6, Issue 30, 2015, Pages 30334-30342

  Tedeschi, Rosamaria ^a   Bidoli, Ettore ^a   Bortolin, Maria Teresa ^a   Schioppa, Ornella ^a   Vaccher, Emanuela ^a   De Paoli, Paolo ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Combination antiretroviral therapy (cART); Endoglin; G CSF; HGF; Kaposi sarcoma (KS)

Indexed keywords

ANGIOPOIETIN 2; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN 9; COLLAGENASE 3; DOXORUBICIN; ENDOGLIN; ENDOTHELIN 1; FOLLISTATIN; GAMMA INTERFERON; GELATINASE A; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; LEPTIN; MACROPHAGE ELASTASE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; SCATTER FACTOR; VASCULOTROPIN; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; CELL SURFACE RECEPTOR; CHEMOKINE; CYTOKINE; ENG PROTEIN, HUMAN; HGF PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; MAINTENANCE THERAPY; MALE; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; REMISSION; TREATMENT RESPONSE; BLOOD; HIV INFECTIONS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; SARCOMA, KAPOSI; TIME FACTOR; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIGENS, CD; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CHEMOKINES; CYTOKINES; ENDOGLIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEPATOCYTE GROWTH FACTOR; HIV INFECTIONS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, CELL SURFACE; REMISSION INDUCTION; SARCOMA, KAPOSI; TIME FACTORS; TREATMENT OUTCOME;

EID: 84945143868     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4571     Document Type: Article

References (37)

1. Bhutani M, Polizzotto MN, Uldrick TS, Yarchoan R. Kaposi Sarcoma-Associated Herpesvirus-Associated Malignancies: Epidemiology, Pathogenesis, and Advances in Treatment. Semin Oncol. 2015; 42:223-246.
2. Yanik EL, Napravnik S, Cole SR, Achenbach CJ, Gopal S, Olshan A, Dittmer DP, Kitahata MM, Mugavero MJ, Saag M, Moore RD, Mayer K, Mathews WC, et al. Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy. Clin Infect Dis. 2013; 57:756-64.
3. Mesri EA, Cesarman E, Boshoff C. Kaposi's sarcoma and its associated herpesvirus. Nat Rev Cancer. 2010; 10:707-19.
4. Douglas JL, Gustin JK, Moses AV, Dezube BJ, Pantanowitz L. Kaposi sarcoma: A triad of viral infection, oncogenesis and chronic inflammation. Transl Biomed. 2010; 1:172.
5. Bortolin MT, Tedeschi R, Bidoli E, Zanussi S, Pratesi C, Vaccher E, Tirelli U, De Paoli P. Multiplex analysis of blood cytokines as a prognostic tool in HIV related non-Hodgkin lymphoma patients: a potential role of interleukin-7 Cytokine. 2012; 60:90-5.
6. Van der Watt JJ, Wilkinson KA, Wilkinson RJ, Heckmann JM. Plasma cytokine profiles in HIV-1 infected patients developing neuropathic symptoms shortly after commencing antiretroviral therapy: a case-control study. BMC Infect Dis. 2014; 14:60-71.
7. Aka PV, Kemp TJ, Rabkin CS, Shiels MS, Polizzotto MN, Lauria C, Vitale F, Pinto LA, Goedert JJ. A multiplex panel of plasma markers of immunity and inflammation in classical kaposi sarcoma. J Infect Dis. 2015; 211:226-9.
8. Bower JE, Bak K, Berger A, Breitbart W, Escalante CP, Ganz PA, Schnipper HH, Lacchetti C, Ligibel JA, Lyman GH, Ogaily MS, Pirl WF, Jacobsen PB. Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical oncology clinical practice guideline adaptation. J Clin Oncol. 2014; 32:1840-50.
9. Vaccher E, Spina M. Kaposi's sarcoma. In: State of the art oncology in Europe. Startoncology. :2014. http://www.startoncology.net.
10. Vaccher E, di Gennaro G, Nasti G, Juzbasic S, Tirelli U. HAART is effective as anti-Kaposi's sarcoma therapy only after remission has been induced by chemotherapy. J Acquir Immune Defic Syndr. 1999; 22:407-8.
11. Martellotta F, Berretta M, Vaccher E, Schioppa O, Zanet E, Tirelli U. AIDS-related Kaposi's sarcoma: state of the art and therapeutic strategies. HIV Res. 2009; 7:634-8.
12. Simonelli C, Tedeschi R, Gloghini A, Bortolin MT, Spina M, Bidoli E, Cinelli R, De Paoli P, Carbone A, Tirelli U. Characterization of immunologic and virological parameters in HIV-infected patients with primary effusion lymphoma during antiblastic therapy and highly active antiretroviral therapy. Clin Infect Dis. 2005; 40:1022-7.
13. Simonelli C, Tedeschi R, Gloghini A, Talamini R, Bortolin MT, Berretta M, Spina M, Morassut S, Vaccher E, De Paoli P, Carbone A, Tirelli U. Plasma HHV-8 viral load in HHV-8-related lymphoproliferative disorders associated with HIV infection. J Med Virol. 2009; 81:888-96.
14. Krown SE, Roy D, Lee JY, Dezube BJ, Reid EG, Venkataramanan R, Han K, Cesarman E, Dittmer DP. Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study. J Acquir Immune Defic Syndr. 2012; 59:447-54.
15. Dezube BJ, Krown SE, Lee JY, Bauer KS, Aboulafia DM. Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study. J Clin Oncol. 2006; 24:1389-94.
16. Koon HB, Krown SE, Lee JY, Honda K, Rapisuwon S, Wang Z, Aboulafia D, Reid EG, Rudek MA, Dezube BJ, Noy A. Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042. J Clin Oncol. 2014; 32:402-8.
17. Bernabeu C, Lopez-Novoa JM, Quintanilla M. The emerging role of TGF-beta superfamily coreceptors in cancer. Biochim Biophys Acta. 2009; 1792:954-73.
18. Ciernik IF1, Krayenbühl Ciernik BH, Cockerell CJ, Minna JD, Gazdar AF, Carbone DP. Expression of transforming growth factor beta and transforming growth factor beta receptors on AIDS-associated Kaposi's sarcoma. Clin Cancer Res. 1995; 1:1119-24.
19. Hawinkels LJ, Kuiper P, Wiercinska E, Verspaget HW, Liu Z, Pardali E, Sier CF, ten Dijke P. Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis. Cancer Res. 2010; 70:4141-50.
20. Li C, Guo B, Wilson PB, Stewart A, Byrne G, Bundred N, Kumar S. Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. Int J Cancer. 2000; 89:122-6.
21. Takahashi N, Kawanishi-Tabata R, Haba A, Tabata M, Haruta Y, Tsai H, Seon BK. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin Cancer Res. 2001; 7:524-32.
22. Li C, Gardy R, Seon BK, Duff SE, Abdalla S, Renehan A, O'Dwyer ST, Haboubi N, Kumar S. Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis. Br J Cancer. 2003; 88:1424-31.
23. Karam JA, Svatek RS, Karakiewicz PI, Gallina A, Roehrborn CG, Slawin KM, Shariat SF. Use of preoperative plasma endoglin for prediction of lymph node metastasis in patients with clinically localized prostate cancer. Clin Cancer Res. 2008; 14:1418-22.
24. Polverini PJ, Nickoloff BJ. Role of scatter factor and the c-met protooncogene in the pathogenesis of AIDSassociated Kaposi's sarcoma. Adv Cancer Res. 1995; 66:235-53.
25. Maier JA, Mariotti M, Albini A, Comi P, Prat M, Comogilio PM, Soria MR. Over-expression of hepatocyte growth factor in human Kaposi's sarcoma. Int J Cancer. 1996; 65:168-72.
26. Montaldo F, Maffé A, Morini M, Noonan D, Giordano S, Albini A, Prat M. Expression of functional tyrosine kinases on immortalized Kaposi's sarcoma cells. J Cell Physiol. 2000; 184:246-54.
27. del Castillo G, Sánchez-Blanco E, Martín-Villar E, Valbuena-Diez AC, Langa C, Pérez-Gómez E, Renart J, Bernabéu C, Quintanilla M. Soluble endoglin antagonizes Met signaling in spindle carcinoma cells. Carcinogenesis. 2015; 36:212-22.
28. Puig L, Fernández-Figueras MT, Penín RM, Esquius M, Alomar A, Ariza A. Differential expression of c-Met in Kaposi's sarcoma according to progression stage and HIV infection status. J Cutan Pathol. 1999; 26:227-31.
29. Tanaka J, Miyake T, Shimizu T, Wakayama T, Tsumori M, Koshimura K, Murakami Y, Kato Y. Effect of continuous subcutaneous administration of a low dose of G-CSF on stem cell mobilization in healthy donors: a feasibility study. Int J Hematol. 2002; 75:489-92.
30. Natori T, Sata M, Washida M, Hirata Y, Nagai R, Makuuchi M. G-CSF stimulates angiogenesis and promotes tumor growth: potential contribution of bone marrowderived endothelial progenitor cells. Biochem Biophys Res Commun. 2002; 297:1058-61.
31. Okazaki T, Ebihara S, Asada M, Kanda A, Sasaki H, Yamaya M. Granulocyte colony-stimulating factor promotes tumour angiogenesis via increasing circulating endothelial progenitor cells and Gr1+CD11b+ cells in cancer animal models. Int Immunol. 2006; 18:1-9.
32. Kuritzkes DR. Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: the role of granulocyte colony-stimulating factor. Clin Infect Dis. 2000; 30:256-60.
33. Cavallin LE, Goldschmidt-Clermont P, Mesri EA. Molecular and cellular mechanisms of KSHV oncogenesis of Kaposi's sarcoma associated with HIV/AIDS. PLoS Pathog. 2014; 10:e1004154.
34. Shebl FM, Yu K, Landgren O, Goedert JJ, Rabkin CS. Increased levels of circulating cytokines with HIV-related immunosuppression. AIDS Res Hum Retroviruses. 2012; 28:809-15.
35. Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol. 1989; 7:1201-7.
36. Tedeschi R, Enbom M, Bidoli E, Linde A, De Paoli P, Dillner J. Viral load of human herpesvirus 8 in peripheral blood of human immunodeficiency virus-infected patients with Kaposi's sarcoma. J Clin Microbiol. 2001; 39:4269-73.
37. Tedeschi R, Marus A, Bidoli E, Simonelli C, De Paoli P. Human herpesvirus 8 DNA quantification in matched plasma and PBMCs samples of patients with HHV8-related lymphoproliferative diseases. J Clin Virol. 2008; 43:255-9.